Wand, Handan <br/><br/>
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.  [electronic resource] 

 -  AIDS (London, England)  Nov 2007 
 - 2445-53 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5571 
<br/><br/><label>Standard No.: </label>10.1097/QAD.0b013e3282efad32  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alkynes<br/>Anthropometry<br/>Anti-HIV Agents--adverse effects<br/>Antiretroviral Therapy, Highly Active--adverse effects<br/>Benzoxazines--adverse effects<br/>Body Constitution<br/>Cardiovascular Diseases--chemically induced<br/>Cyclopropanes<br/>Diabetes Mellitus, Type 2--chemically induced<br/>Disease Progression<br/>Epidemiologic Methods<br/>Female<br/>HIV Infections--drug therapy<br/>Humans<br/>Male<br/>Metabolic Syndrome--chemically induced<br/>Middle Aged<br/>Nelfinavir--adverse effects<br/>Reverse Transcriptase Inhibitors--adverse effects